- Email: [email protected]
Statin Treatment for Erectile Function
LETTERS TO THE EDITOR
ERRATA VARICOCELECTOMY USING ISOSULFAN BLUE Volume 175, Number 3, Page 1049: The term “ethical approval” does not reflect institutional review board (IRB) approval. This study was performed in accordance with Austrian federal law requiring no IRB approval for such a study setting (§8 Abs 3 KAKuG). All legal requirements were fully implemented. ESTABLISHING PREVALENCE OF INCONTINENCE STUDY Volume 179, Number 4, Page 1455: The name of the third author of this article is Divya A. Patel. OXIDATIVE STRESS IN CULTURED RENAL TUBULAR CELLS Volume 179, Number 4, Page 1620: The correspondent for this article is Hyeon Hoe Kim, Department of Urology, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; e-mail: [email protected]. STATIN TREATMENT FOR ERECTILE FUNCTION Volume 179, Number 4, Part 2, Program Abstract Book, Page 554: The correct Abstract 1621 is as follows: THE EFFICACY OF STATIN TREATMENT FOR EARLY RECOVERY OF ERECTILE FUNCTION AFTER NERVESPARING RADICAL RETROPUBIC PROSTATECTOMY Sung Kyu Hong*, Seongnam, Kyunggi-do, Republic of Korea, Byung Kyu Han, Jae Seung Jeong, Ki Hyuk Moon, Seong Jin Jeong, Hwang Choi, Seoul, Republic of Korea, Seok-Soo Byun, Sang Eun Lee, Seongnam, Kyunggi-do, Republic of Korea. INTRODUCTION AND OBJECTIVE: Today, erectile dysfunction still lingers as a major postoperative problem following radical retropubic prostatectomy (RRP). Meanwhile, statins, which are known to have protective effect on vascular endothelium leading to increased activity of nitric oxide, may also have protective effect on corporal endothelium as well. Also, statin class of drugs are generally much less costly compared with phosphodiesterase (PDE) 5 inhibitors In addition, some have recently reported that statins may have neuroprotective effect as well. Thus, we prospectively investigated whether postoperative use of a statin would contribute to earlier recovery of erectile function in men who underwent bilateral nerve-sparing RRP for clinically localized prostate cancer. METHODS: Fifty potent men without hypercholesterolemia undergoing bilateral nerve-sparing RRP for clinically localized prostate cancer were prospectively randomized into two equal groups. In group 1, patients were instructed to take only 50 mg/day sildenafil, if needed, following discharge from hospital after RRP. Meanwhile in group 2, patients were prescribed to take atorvastatin at a dose of 10 mg/day from postoperative day 1 to 90 and were also instructed to take sildenafil as in group 1. Postoperatively, patients’ status regarding potency and adverse events were assessed at 6 months after surgery. Patients were considered potent after surgery when, with or without sildenafil, they had a total International Index of Erectile Function (IIEF)-5 score of ⱖ 16 or score of ⱖ 4 were obtained for the question: “over the past 4 weeks, when you attempted sexual intercourse, how often was it satisfactory for you?”. RESULTS: Two groups demonstrated no significant differences regarding various baseline factors including IIEF-5 scores. Group 2 demonstrated significantly higher postoperative IIEF-5 score than group 1 at 6 months after RRP (p ⫽ 0.003). Meanwhile, the proportions of potent subjects as judged by pre-set definition at 6 months after RRP were 26.1% in group 1 and 55% in group 2 (p ⫽ 0.068). Also, 17.4% and 40% reported achieving intercourse by vaginal penetration without the aid of PDE5 inhibitor in group 1 and 2, respectively (p ⫽ 0.172). No serious adverse events associated with medication were reported. CONCLUSIONS: Postoperative treatment with atorvastatin in men who report normal erectile function preoperatively may contribute to earlier recovery of erectile function after nerve-sparing RRP. Source of Funding: Seoul National University Bundang Hospital Research Fund.
415
ERRATA VARICOCELECTOMY USING ISOSULFAN BLUE Volume 175, Number 3, Page 1049: The term “ethical approval” does not reflect institutional review board (IRB) approval. This study was performed in accordance with Austrian federal law requiring no IRB approval for such a study setting (§8 Abs 3 KAKuG). All legal requirements were fully implemented. ESTABLISHING PREVALENCE OF INCONTINENCE STUDY Volume 179, Number 4, Page 1455: The name of the third author of this article is Divya A. Patel. OXIDATIVE STRESS IN CULTURED RENAL TUBULAR CELLS Volume 179, Number 4, Page 1620: The correspondent for this article is Hyeon Hoe Kim, Department of Urology, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; e-mail: [email protected]. STATIN TREATMENT FOR ERECTILE FUNCTION Volume 179, Number 4, Part 2, Program Abstract Book, Page 554: The correct Abstract 1621 is as follows: THE EFFICACY OF STATIN TREATMENT FOR EARLY RECOVERY OF ERECTILE FUNCTION AFTER NERVESPARING RADICAL RETROPUBIC PROSTATECTOMY Sung Kyu Hong*, Seongnam, Kyunggi-do, Republic of Korea, Byung Kyu Han, Jae Seung Jeong, Ki Hyuk Moon, Seong Jin Jeong, Hwang Choi, Seoul, Republic of Korea, Seok-Soo Byun, Sang Eun Lee, Seongnam, Kyunggi-do, Republic of Korea. INTRODUCTION AND OBJECTIVE: Today, erectile dysfunction still lingers as a major postoperative problem following radical retropubic prostatectomy (RRP). Meanwhile, statins, which are known to have protective effect on vascular endothelium leading to increased activity of nitric oxide, may also have protective effect on corporal endothelium as well. Also, statin class of drugs are generally much less costly compared with phosphodiesterase (PDE) 5 inhibitors In addition, some have recently reported that statins may have neuroprotective effect as well. Thus, we prospectively investigated whether postoperative use of a statin would contribute to earlier recovery of erectile function in men who underwent bilateral nerve-sparing RRP for clinically localized prostate cancer. METHODS: Fifty potent men without hypercholesterolemia undergoing bilateral nerve-sparing RRP for clinically localized prostate cancer were prospectively randomized into two equal groups. In group 1, patients were instructed to take only 50 mg/day sildenafil, if needed, following discharge from hospital after RRP. Meanwhile in group 2, patients were prescribed to take atorvastatin at a dose of 10 mg/day from postoperative day 1 to 90 and were also instructed to take sildenafil as in group 1. Postoperatively, patients’ status regarding potency and adverse events were assessed at 6 months after surgery. Patients were considered potent after surgery when, with or without sildenafil, they had a total International Index of Erectile Function (IIEF)-5 score of ⱖ 16 or score of ⱖ 4 were obtained for the question: “over the past 4 weeks, when you attempted sexual intercourse, how often was it satisfactory for you?”. RESULTS: Two groups demonstrated no significant differences regarding various baseline factors including IIEF-5 scores. Group 2 demonstrated significantly higher postoperative IIEF-5 score than group 1 at 6 months after RRP (p ⫽ 0.003). Meanwhile, the proportions of potent subjects as judged by pre-set definition at 6 months after RRP were 26.1% in group 1 and 55% in group 2 (p ⫽ 0.068). Also, 17.4% and 40% reported achieving intercourse by vaginal penetration without the aid of PDE5 inhibitor in group 1 and 2, respectively (p ⫽ 0.172). No serious adverse events associated with medication were reported. CONCLUSIONS: Postoperative treatment with atorvastatin in men who report normal erectile function preoperatively may contribute to earlier recovery of erectile function after nerve-sparing RRP. Source of Funding: Seoul National University Bundang Hospital Research Fund.
415